New MI - Microarrays Inc. Website Showcases Advanced Microarray Capabilities for Research and Diagnostic Assay Applications

Share Article

Microarrays Inc. Launches its Newly Designed Website at Providing a Comprehensive Overview of Their Cutting-Edge Manufacturing Services for Array-based Research and Diagnostic Tools.

MI, also known as Microarrays Inc, has launched its newly designed website, at The dramatically redesigned site provides potential clients with a comprehensive overview of the cutting-edge manufacturing services for array-based research and diagnostic tools offered by MI.

MI capabilities in the proteomics, assay development and diagnostic markets are prominently featured reflecting the growing demand for new tools for the exciting areas of clinical investigation and research. The new website offers information on refinements to the established MI ReadyArrays for assessing gene expression. Researchers will find detailed information for each of the 40+ organisms offered.

Echoing the excitement of all those involved in the new website’s design and construction, Joel Peek, MI President and CEO, commented, “The new web site illustrates many of the capabilities that MI has provided to the research and commercial communities for over a decade now. It provides an enhanced snapshot of the experience and expertise we’ve developed as a large-scale manufacturing partner and reflects our abilities to respond to client needs, whether they are in the area of product development or diagnostics or healthcare, etc. We’re excited to showcase our abilities and look forward to new dialogs and challenges.“

About MI
MI’s corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010. In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Andrew Jennings
Visit website